Aligos Therapeutics presented positive data for its chronic hepatitis B (CHB) candidate, ALG-000184, at The Liver Meeting (TLM) 2024. Data from up to 84 weeks of 300 mg ALG-000184 monotherapy showed sustained HBV DNA suppression in 100% of HBeAg-positive subjects (7/7) and 100% of HBeAg-negative subjects by Week 24. No viral resistance or breakthrough was observed with monotherapy treatment.
Multi-log reductions in HBsAg, HBeAg, and HBcrAg were observed in HBeAg-positive subjects, with HBcrAg decline also seen in HBeAg-negative subjects. The drug continued to be well tolerated in both patient populations. These results strengthen the belief that ALG-000184 has potential as a first-line therapy for chronic suppression and as a backbone for functional cure regimens.
Additionally, the company presented data for ALG-055009 in MASH patients, reiterating robust reductions in liver fat content from the Phase 2a HERALD study. A subgroup analysis showed that 11 of 14 subjects on stable GLP-1 agonist therapy treated with ALG-055009 experienced liver fat decreases. This suggests a role for ALG-055009 in combination therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.